BioSpace News Archive

Patient Stories Day on October 13th, 2018, marked the end of another successful National Obesity Care Week. NOCW is a national campaign aimed to change the way we care about obesity by creating a society that understands, respects and accepts the complexities of obesity and values science-based care.

Technology supported by Dr Jonathan Milner in his ELRIG Plenary Address

Craig Brammer appointed to lead the organization forward

Mercaptor Discoveries announced today that Dr. Adriano Aguzzi, MD, PhD, is heading up the formation of its Scientific Advisory Board (SAB).

Shares of Bone Therapeutics have plunged more than 26 percent on the Euronext Brussels stock exchange after the Belgium-based company halted a Phase III trial in osteonecrosis of the hip after an interim analysis indicated the study would not meet endpoints.

Cambridge, Mass.-based Biogen exercised its option to acquire additional shares of South Korea’s Samsung Bioepis. Samsung Bioepis focuses on developing biosimilar drugs and is a joint venture between Samsung Biologics and Biogen formed in 2012.

Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.

PARAS BIOPHARMACEUTICALS FINLAND OY is currently enhancing its GMP, quality systems and production facilities for biopharmaceuticals – also known as biologics – with significant investments in new infrastructure and equipment.

Pharnext SA announced today its financial results for first-half 2018.

Sareum Holdings plc announces that it has raised £850,000, before expenses, through a placement of 130,769,231 new ordinary shares of 0.025p each in the capital of the Company (the “Placing Shares”) through a third party licensed dealer acting solely as a placing agent to this transaction at 0.65p per share.